Abstract
Long term antiviral therapy with nucleos(t)ide analogs (NAs) may lead to the emergence of drug-resistance viral mutants in chronic hepatitis B virus (HBV) patient. The purpose of this study was to identify adefovir dipivoxil (ADV) resistance mutations of HBV polymerase and determine effective drugs to replace ADV. The reverse transcriptase (RT) coding region was PCR-amplified using HBV DNA extracted from patient blood samples and sequenced. Nineteen substitution mutations were detected. Among them, rtN238R, rtT240Y and rtN248H were often observed in patients receiving ADV administration. These three potential drug resistant sites were introduced into HBV replication-competent plasmids. The in vitro susceptibility of both wild-type (WT) and mutant-type (MT) HBV to NAs was analyzed by Southern blotting and quantitative real-time PCR. The rtN238R, rtT240Y and rtN248H substitutions had no obvious effect on HBV DNA replication or gene expression. The in vitro susceptibility analysis showed that rtN238R, rtT240Y and rtN248H substitutions were responsible for the reduced susceptibility to ADV, and demonstrated a 5.42-, 2.89- and 5.72-fold increase in resistance towards ADV, respectively. However, HBV harbored these mutations retained normal susceptibility to LMV, LdT, ETV and TDF.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol, 2007, 13: 48–64
Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: Removal of genome-linked protein. J Virol, 2007, 81: 6164–6174
Mizokami M, Orito E, Ohba K, et al. Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol, 1997, 44(Suppl 1): S83–90
Lee W M. Hepatitis B virus infection. N Engl J Med, 1997, 337: 1733–1745
Behal R, Jain R, Behal K K, et al. Seroprevalence and risk factors for hepatitis B virus infection among general population in northern India. Arq Gastroenterol, 2008, 45: 137–140
Mahoney F J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev, 1999, 12: 351–366
Schildgen V, Ziegler S, Tillmann R L, et al. Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance-A scholarly case. Virol J, 2010, 7: 167
Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell, 1982, 29: 403–415
Gunther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res, 1999, 52: 25–137
Yuen M F, Lai C L. Treatment of chronic hepatitis B. Lancet Infect Dis, 2001, 1: 232–241
Fung J, Lai C L, Seto W K, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother, 2011, 66: 2715–2725
Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 2009, 137: 1593–1608
Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res, 2006, 71: 206–215
Kwon H, Lok A S. Hepatitis B therapy. Nat Rev, 2011, 8: 275–284
Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “Fingers” Subdomain of the viral polymerase selected as a consequence of mutations in the overlappings gene. Virology, 2002, 299: 88–99
Brunelle M N, Jacquard A C, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 2005, 41: 1391–1398
Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol, 2006, 80: 643–653
Osiowy C, Villeneuve J P, Heathcote E J, et al. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol, 2006, 44: 1994–1997
Leung N. Viral resistance in HBV infection: Diagnosis, implications and management. Trop Gastroenterol, 2008, 29: 123–128
Amini Bavil Olyaee S, Herbers U, Sheldon J, et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology, 2009, 49: 1158–1165
Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther, 2005, 10: 727–734
Delaney W E, Ray A S, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother, 2006, 50: 2471–2477
Wu C, Deng W, Deng L, et al. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol, 2012, 86: 4658–4669
Lei Y C, Hao Y H, Zhang Z M, et al. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol, 2006, 12: 4492–4497
Qiu J, Qin B, Rayner S, et al. Novel evidence suggests hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol Sin, 2011, 26: 131–138
Kain S R. Use of secreted alkaline phosphatase as a reporter of gene expression in mammalian cells. Methods Mol Biol, 1997, 63: 49–60
Pan X B, Wei L, Han J C, et al. Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. Antiviral Res, 2011, 89: 109–114
Guarnieri M, Kim K H, Bang G, et al. Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol, 2006, 80: 587–595
Meng Z, Xu Y, Wu J, et al. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods, 2008, 150: 27–33
Untergasser A, Zedler U, Langenkamp A, et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology, 2006, 43: 539–547
Santantonio T, Fasano M, Durantel S, et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther, 2009, 14: 557–565
Margeridon Thermet S, Shulman N S, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis, 2009, 199: 1275–1285
Milazzo L, Corbellino M, Foschi A, et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis, 2012, 14: 95–98
Wu C, Zhang X, Tian Y, et al. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol, 2010, 91: 483–492
Lok A S. Hepatitis B infection: Pathogenesis and management. J Hepatol, 2000, 32: 89–97
Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs, 1999, 58: 101–141
Liu B M, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive chinese patients. Antiviral Res, 2010, 85: 512–519
Tan J, Degertekin B, Wong S N, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol, 2008, 48: 391–398
Galmarini C M, Mackey J R, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Leukemia, 2001, 15: 875–890
Cha C K, Kwon H C, Cheong J Y, et al. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol, 2009, 81: 417–424
Lee Y S, Suh D J, Lim Y S, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 2006, 43: 1385–1391
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Qin, B., Pei, R., He, T. et al. Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir. Chin. Sci. Bull. 58, 1760–1766 (2013). https://doi.org/10.1007/s11434-013-5770-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-013-5770-x